Literature DB >> 21836028

The Manitoba Inflammatory Bowel Disease Cohort Study: a prospective longitudinal evaluation of the use of complementary and alternative medicine services and products.

Patricia Rawsthorne1, Ian Clara, Lesley A Graff, Kylie I Bernstein, Rachel Carr, John R Walker, Jason Ediger, Linda Rogala, Norine Miller, Charles N Bernstein.   

Abstract

OBJECTIVE: To determine the prevalence of complementary and alternative medicine (CAM) use over time in a population-based cohort of patients with inflammatory bowel disease (IBD).
METHODS: The Manitoba IBD Cohort Study is a longitudinal, population-based study of multiple determinants of health outcomes in an IBD cohort. Participants completed semi-annual surveys, and annual in-person interviews. Enquiries about the use of 12 types of CAM service providers and 13 CAM products, based on items from a national survey, were included at months 0, 12, 30 and 54.
RESULTS: Overall, 74% of respondents used a CAM service or product in the 4.5-year period, with approximately 40% using some type of CAM at each time point, and 14% using CAM consistently at every time point. There was a trend for women to use CAM more than men; there was no difference in CAM use between patients with Crohn's disease and those with ulcerative colitis. The most often used CAM services (on average) were massage therapy (30%) and chiropractic (14%), physiotherapy (4%), acupuncture (3.5%) and naturopathy/homeopathy (3.5%). A wide range of CAM products were used, with Lactobacillus acidophilus (8%), fish and other oils (5.5%), glucosamine (4%) and chamomile (3.5%) as the most common. On average, only 18% of consumers used CAM for their IBD, so the majority chose it for other problems. There were no differences in psychological variables between CAM users and non-users.
CONCLUSIONS: Those with IBD commonly try CAM, although very few use these approaches regularly over the years. CAM is not usually used by patients with IBD for disease management, but clinicians should be aware that many will test the services and products.

Entities:  

Mesh:

Year:  2011        PMID: 21836028     DOI: 10.1136/gutjnl-2011-300219

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  23 in total

1.  Doctor communication quality and Friends' attitudes influence complementary medicine use in inflammatory bowel disease.

Authors:  Réme Mountifield; Jane M Andrews; Antonina Mikocka-Walus; Peter Bampton
Journal:  World J Gastroenterol       Date:  2015-03-28       Impact factor: 5.742

Review 2.  Inflammatory bowel disease: a Canadian burden of illness review.

Authors:  Angela Rocchi; Eric I Benchimol; Charles N Bernstein; Alain Bitton; Brian Feagan; Remo Panaccione; Kevin W Glasgow; Aida Fernandes; Subrata Ghosh
Journal:  Can J Gastroenterol       Date:  2012-11       Impact factor: 3.522

Review 3.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 4.  Drug-Herb Interactions in the Elderly Patient with IBD: a Growing Concern.

Authors:  Haider Rahman; Marina Kim; Galen Leung; Jesse A Green; Seymour Katz
Journal:  Curr Treat Options Gastroenterol       Date:  2017-12

Review 5.  Complementary and Alternative Medicine Use Is Prevalent Among Patients with Gastrointestinal Diseases.

Authors:  Adelina Hung; Nancy Kang; Andrea Bollom; Jacqueline L Wolf; Anthony Lembo
Journal:  Dig Dis Sci       Date:  2015-01-04       Impact factor: 3.199

Review 6.  Challenges in designing a national surveillance program for inflammatory bowel disease in the United States.

Authors:  Millie D Long; Susan Hutfless; Michael D Kappelman; Hamed Khalili; Gilaad G Kaplan; Charles N Bernstein; Jean Frederic Colombel; Corinne Gower-Rousseau; Lisa Herrinton; Fernando Velayos; Edward V Loftus; Geoffrey C Nguyen; Ashwin N Ananthakrishnan; Amnon Sonnenberg; Andrew Chan; Robert S Sandler; Ashish Atreja; Samir A Shah; Kenneth J Rothman; Neal S Leleiko; Renee Bright; Paolo Boffetta; Kelly D Myers; Bruce E Sands
Journal:  Inflamm Bowel Dis       Date:  2014-02       Impact factor: 5.325

Review 7.  Treatment of IBD: where we are and where we are going.

Authors:  Charles N Bernstein
Journal:  Am J Gastroenterol       Date:  2014-12-09       Impact factor: 10.864

8.  Complementary and alternative medicine use by US adults with gastrointestinal conditions: Results from the 2012 National Health Interview Survey.

Authors:  Michelle L Dossett; Roger B Davis; Anthony J Lembo; Gloria Y Yeh
Journal:  Am J Gastroenterol       Date:  2014-07-08       Impact factor: 10.864

9.  Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives.

Authors:  Soo Jung Park; Won Ho Kim; Jae Hee Cheon
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

10.  Longitudinal use of complementary and alternative medicine among older adults with radiographic knee osteoarthritis.

Authors:  Shibing Yang; Catherine E Dubé; Charles B Eaton; Timothy E McAlindon; Kate L Lapane
Journal:  Clin Ther       Date:  2013-10-18       Impact factor: 3.393

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.